Introduction {#s1}
============

A clinical diagnosis of primary ovarian insufficiency (POI) is defined by the presence of primary or secondary amenorrhea (PA or SA) and hypergonadotropic hypogonadism, occurring before the age of 40 ([@DEU149C30]; [@DEU149C7]). This condition has previously also been termed premature ovarian failure in patients with SA and gonadal dysgenesis in PA.

POI pathogenesis can be divided into follicle dysfunction and follicle depletion. Follicle depletion can be caused by a small initial germ cell count or a rapid germ cell loss. External factors, such as surgery, irradiation and infection as well as autoimmune and metabolic disorders also lead to POI. Most cases however remain idiopathic, and there is a significant genetic component ([@DEU149C38]; [@DEU149C32]). The most common are chromosomal aberrations including Turner\'s syndrome ([@DEU149C4]). Premutation of the *FMR1* gene is responsible for 2--5% of sporadic cases with POI presenting with SA ([@DEU149C42]; [@DEU149C7]).

Other known genetic causes are mutations in genes for oocyte-secreted factors, *GDF9* (growth differentiation factor 9) and *BMP15* ([@DEU149C9]; [@DEU149C20]), for oocyte nuclear transcription factors *NOBOX* and *FIGLA* ([@DEU149C33]; [@DEU149C47]) and for the hormone receptors *FSHR* and *NR5A1* ([@DEU149C2]; [@DEU149C16]). However, the majority (90%) of patients with POI do not receive a molecular diagnosis ([@DEU149C30] and it is likely that many causative genes still remain unknown.

By genome-wide detection of small genomic rearrangements, it is possible to identify novel genes involved in ovarian development, both on the X chromosome and on autosomes. The aim of this study was to identify novel candidate genes for ovarian development and function by investigating submicroscopic genetic imbalances in patients with POI. A 1 M array-CGH (comparative genomic hybridization) platform with 2.2 kb probe spacing for whole genome coverage and enrichment targeting 78 genes involved in gonadal development was used. At present, all studies reporting copy number variants (CNVs) in patients with POI by array-CGH have used lower resolution platforms ([@DEU149C1]; [@DEU149C22]; [@DEU149C25]). Studies using whole genome SNP array ([@DEU149C27]) and targeted analysis of the X chromosome using array-based techniques have also been reported ([@DEU149C11]; [@DEU149C34]; [@DEU149C17]).

Materials and Methods {#s2}
=====================

Patients {#s2a}
--------

Fifty-four patients with POI (23 with PA, 31 with SA) referred to the Clinical Genetic Laboratory of Karolinska University Hospital Stockholm, Sweden, were included in the study. Samples from 26 patients (17 with PA and 9 with SA) were available for array-CGH experiments.

The diagnosis of POI was set by PA or SA in a girl with female external genitalia as well as internal Müllerian structures (uterus) and hypergonadotropic hypogonadism (FSH \> 30 IU/l), determined twice. In the group with SA the overall median age at diagnosis was 22 years (12--37) (Table [I](#DEU149TB1){ref-type="table"}). The nine patients with SA included in the array-CGH experiments were diagnosed at a median age of 16 (13--22) years. Table IClinical overview of investigated patients.Clinical dataPA (*n* = 23)SA (*n* = 31)Median age at diagnosis, years (range)16 (13--18)22 (12--37)Median age at menarche, years (range)--13 (10--15)Median FSH level at diagnosis, IU/l (range)^a^89 (39--150)80 (34--155)Swedish Caucasian, *n* (%)17 (74)26 (84)Known heredity for POI, *n* (%)1 (4)6 (19)Spontaneous conception before diagnosis, *n* (%)--11 (35)[^1]

One patient with PA has several affected sisters with POI who did not want to be included in the study. Among patients with SA, four have mothers with POI, one a sister with POI and one an affected paternal aunt, who is included in the study.

None of the patients had undergone previous ovarian surgery, chemotherapy or radiotherapy or presented with syndromic forms of POI. Five patients presented with hypothyroidism with anti-thyroid autoantibodies, after POI diagnosis in four with SA, and at 11 years of age in one patient with PA. None had autoantibodies against adrenal cortex or 21-hydroxylase protein.

Nine patients with POI underwent laparoscopy with diagnostic ovarian biopsies. In four patients with PA, streak gonads with no visible follicles were found. Three patients with SA also had streak gonads with no visible follicles. One patient with SA at 23 had multiple primordial follicles and one patient with SA at 15 had a few visible primordial and primary follicles.

Ethical approval {#s2b}
----------------

All participants gave informed consent and the regional Ethics Committee at Karolinska Institutet, Sweden, approved the study with registration number 2007/263-31/2 and 2011/276-32.

Genetic investigation {#s2c}
---------------------

A 46, XX karyotype in peripheral blood was confirmed in all but in Patient 24 in whom a balanced Robertsonian translocation identified (45, XX, der (13; 14)) was not considered causative.

Sex chromosome mosaicism was excluded using fluorescent *in situ* hybridization and DNA probes from chromosomes X and Y on peripheral blood smears, and when available, on touch preparations from gonadal tissue. Genetic investigations included sequencing of the *NR5A1*, *BMP15*, *FSHR*, *FIGLA*, *NOBOX* and *GDF9* genes. *FMR1* mutations were also excluded in patients with SA.

Controls {#s2d}
--------

DNA samples from 95 healthy women were collected. All women were above the age of 40 and had given birth to at least one child. The exclusion criteria were previous egg donation, *in vitro* fertilization, infertility treatment or menopause before the age of 40.

DNA extraction {#s2e}
--------------

DNA was extracted from peripheral blood lymphocytes. Some samples were further purified using the QiAmp DNA minikit (QIAGEN, Sweden) to achieve acceptable quality values for array-CGH analysis.

Array-CGH {#s2f}
---------

Twenty-six unrelated patients with POI were analyzed using a customized 1 M oligomarker array-CGH platform developed at Oxford Gene Technology (OGT, UK). In addition to whole genome coverage, the platform is enriched with probes targeting 78 genes implicated in sex development ([Supplementary data, Table SI](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/deu149/-/DC1)). The theoretical average probe resolution is 2.2 kb.

Preparation of labeled DNA and subsequent hybridization were performed according to the 'Agilent oligonucleotide array-based CGH for genomic DNA analysis' protocol (v6.2) and as previously described ([@DEU149C31]). A commercial DNA sample with pooled human genomic DNA from 10 female controls (Promega, Sweden) was used as reference DNA.

Data was analyzed using the Cytosure interpret software v3.4.3 (OGT). Circular binary segmentation analysis to detect copy number changes was performed using the following parameters: minimum probe count: 5, threshold for gains: 0.35, threshold for losses: 0.65, chromosome average method: median segment.

By comparing data with the online database of genomic variation (DGV) version 10 released Nov 2010 ([@DEU149C15]), common CNVs found in healthy control samples were excluded from further investigation. This exclusion was done with caution, as phenotypic effects of genetic imbalances affecting sexual development can be dependent on chromosomal sex. This information is not always available for controls included in the DGV. Aberrations only partially overlapping with rare reported CNVs were not excluded. Small intronic variations and aberrations not affecting genes were excluded after verification that they were not located just upstream or downstream a known gene causing disorders of sex development as a positional effect should then be considered.

Multiplex ligation-dependent probe amplification {#s2g}
------------------------------------------------

Multiplex ligation-dependent probe amplification (MLPA) ([@DEU149C37]) probes were designed according to the recommendations by [@DEU149C39]) and combined in different probe sets ([Supplementary data, Table SII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/deu149/-/DC1)). The reference probes and the pilot probe used have been described earlier ([@DEU149C3]).

MLPA reactions were performed according to the EK1 reagent kit (MRC-Holland, the Netherlands) recommendations using 200 ng of DNA and the in-house designed probe set, as previously described ([@DEU149C3]). The reference DNA sample used for array-CGH was used as a control in all runs, along with at least another control DNA.

Confirmation of array-CGH findings {#s2h}
----------------------------------

Copy number variations left after exclusion criteria were confirmed by MLPA using two probes per aberration. When available, parental samples were analyzed for control of inheritance. Trace data were exported and analyzed in an Excel 2007 spreadsheet. Each sample\'s peak heights were normalized to the average peak height of the reference probes and subsequently normalized to the average peak height of the control samples. The analysis was accepted if the reference probe ratios were between 0.8 and 1.2. Threshold values for deletions and duplications were set at 0.75 and 1.25, respectively.

MLPA for *GDF9* {#s2i}
---------------

A specific synthetic probe set for MLPA analysis of the *GDF9* gene was designed. Two probes were placed in each exon, two upstream *GDF9* and one probe downstream (Fig. [1](#DEU149F1){ref-type="fig"}E). The probe set was validated for consistency by analysis of 10 healthy controls, with a standard deviation \<0.1 for each probe. Trace data were analyzed using the GeneMarker v1.90 (Soft Genetics, USA) software using internal control probe normalization, quantification by peak height and ratio threshold values for deletion and duplication were 0.75 and 1.3, respectively. Figure 1*GDF9* duplication. (**A**) Representation of an array-CGH result from the Cytosure software. The duplicated segment is indicated by blue background with a positive baseline offset. Blue dispersed dots represent oligomarkers. Blue arrows on bottom indicate gene location and purple smaller arrows represent exons. Black horizontal line on bottom represents location of duplication. Chromosome ideogram shown on top with the current segment magnification indicated by blue background color. (**B**) Schematic representation of the *GDF9* gene. The ATG indicates the initiation of translation. Red dots represent NBE. Violet dot represents the E-box. Yellow arrow indicates the duplicated segment. Black and blue arrows represent PCR primers for wild-type allele (wt) and for duplication breakpoint amplification, respectively. (**C**) Schematic representation of the duplication. The green line represents the PCR product containing the duplication junction. (**D**) Breakpoint characterization. Gel image of amplified PCR breakpoint fragment. P, patient; C, control; B, blank; L, ladder. Electropherograms with sequence of the breakpoint (in the middle), partially aligned with the wt allele (upper and lower electropherograms). (**E**) Representation from the UCSC genome browser, GRCh37/hg19 assembly. Horizontal yellow arrow line indicates the duplicated segment. Locations of NBE (TAATTA, TAATTG) and E-box (CAGCTG) are shown as vertical red and purple lines, respectively. Vertical black boxes represent MLPA probes.

Patient cohort and control screening {#s2j}
------------------------------------

A specific synthetic probe set for MLPA analysis of array findings was designed, using one probe per each novel candidate copy number variation identified by array-CGH experiments. In addition, one probe within the keratin-associated protein (*KRTAP*)*2-1* and the *KRTAP2-2* gene, respectively, were included. The probe set was validated for consistency. Trace data were analyzed with GeneMarker v1.90.

Sequencing of TSPYL6, KRTAP2-3 and KRTAP2-4 {#s2k}
-------------------------------------------

The single exon genes *TSPYL6*, *KRTAP2-3* and *KRTAP2-4*, including part of the UTRs, were amplified by PCR using DyNAzyme EXT polymerase. Primers were designed using Primer3 software ([@DEU149C19]; [@DEU149C41]) ([Supplementary data, Table SIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/deu149/-/DC1)).

PCR products were cleaned and sequenced using the ABI BigDye Terminator v3.1 kit (Applied Biosystems, Sweden). Electropherograms were analyzed against the reference sequences: NM_001003937.2 for *TSPYL6*, NM_001165252.1 for *KRTAP2-3* and NM_033184.3 for *KRTAP2-4*, using the SeqScape v2.5 program (Applied Biosystems).

Characterization of the GDF9 duplication {#s2l}
----------------------------------------

Primers for the amplification and sequencing of the duplication junction were designed using Primer 3 software ([@DEU149C36]) ([Supplementary data, Table SIII](http://humrep.oxfordjournals.org/lookup/suppl/doi:10.1093/humrep/deu149/-/DC1)) with the hypothesis of a tandem duplication.

*In silico* analysis {#s2m}
--------------------

For all identified candidate genes the following databases were searched for information. Relevant data are presented in the discussion section.

NCBI (<http://www.ncbi.nlm.nih.gov/>) including PubMed, UCSC (<http://genome.ucsc.edu/>) ([@DEU149C10]), GeneCards (<http://www.genecards.org/>), The Human Protein Atlas (<http://www.proteinatlas.org/>) ([@DEU149C40]), Gene expression profiles during sex determination by Dr Serge Nef (<http://nef.unige.ch/microarrays.php>) ([@DEU149C29]), DECIPHER (Database of Chromosomal Imbalance and Phenotype in Humans Using Ensembl Resources) (<http://decipher.sanger.ac.uk/>), LifeMap Database of Embryonic development, Stem Cell Research and Regenerative Medicine (<http://discovery.lifemapsc.com>) ([@DEU149C12]).

Polyphen2 was used to evaluate amino acid substitutions (<http://genetics.bwh.harvard.edu/pph2>).

Results {#s3}
=======

Array-CGH {#s3a}
---------

A total of 1720 aberrations were detected by array-CGH analysis of 26 samples with an average of 66 changes per patient (ranging from 29 to 142). After exclusion criteria, 13 copy number changes remained, 6 in the PA group and 7 in the SA (Table [II](#DEU149TB2){ref-type="table"}). Two pairs of patients carried the same aberration and one patient carried 3 changes, leaving 11 unique copy number changes identified in a total of 11 patients. One aberration affected the *GDF9* gene, already associated with POI, the other 10 changes unraveled novel candidate regions. All aberrations were confirmed by MLPA. When possible, inheritance pattern was investigated. Table IIResults from 26 patients, copy numbers shown after application of exclusion criteria.Pat. no.Age at amen.Chr. bandStartEndSize (kb)Probe countDel/dupGene(s)InheritanceOther information1PA2p16.2542965465439810010239 Del*ACYP2, TSPYL6*Not maternal--2PA----------------Ovarian biopsy3PA15q26.292580470926199183917Del*MCTP2*Maternal--4PA3p21.31475885584772327513554Dup*SMARCC1*, *CSPG5*MaternalMother breast cancer 41 years5PA15q26.292580470926199183917Del*MCTP2*Paternal--6PA------------------7PA------------------8PA------------------9PA12p13.33266667127189055215Dup*CACNA1C*Maternal--10PA------------------11PA------------------12PA15q25.28191799581997930825Dup*SH3GL3*Maternal--13PA------------------14PA------------------15PA------------------16PA------------------17PA------------------1816 years------------------1914 years19p13.33688186381611712851Del*RAX2*, *TJP3*, *ZFR2*, *MRPL54*, *APBA3*, *MATK*MaternalHypothyroidism ovarian biopsyXp22.33152922115726944317Dup*P2RY8*, *ASMTL*Not maternal--17q21.2364652903647379295Del*KRTAP2-3*, *KRTAP2-4*Not maternal--2015 years5q31.11322282661322287400.57Dup*GDF9*NA--2122 years2p11.2846204558479166117157Del*DNAH6*NAPaternal aunt POI 342220 years17q21.2364652903647379295Del*KRTAP2-3*, *KRTAP2-4*^a^Mother hemizygousHypothyroidism consanguinity mother with bilateral breast cancer2317 years2q342107034812107394673614Del*KANSL1L*Maternal--2421 years----------------45,XX,der(13;14) Ovarian biopsy2515 years------------------2613 years----------------Hypothyroidism with anti-TPO ovarian biopsy[^2][^3]

The entire patient cohort of 54 patients with POI and 95 healthy controls were screened by MLPA for additional cases with copy number changes within the novel candidate regions. One patient and two controls were heterozygous for *KRTAP2-3* and *KRTAP2-4* deletion*.* One control was hemizygous for the *KRTAP2-2* gene. No other patient or control was found to carry any other identified aberration.

GDF9 duplication investigation and GDF9 MLPA analysis {#s3b}
-----------------------------------------------------

A duplication between 475 and 1729 bp within the *GDF9* gene was identified by array-CGH in Patient 20. We amplified the duplication junction (Fig. [1](#DEU149F1){ref-type="fig"}D) and by sequencing, we confirmed a tandem head-to-tail duplication of 475 bp containing the first part of the 5′ UTR and a short upstream DNA sequence (Chr5.hg19:g.132,201,170_132,201,644dup).

Analysis of the entire patient cohort by an MLPA probe set for the identification of deletions/duplications within or encompassing *GDF9* did not identify any additional case.

Sequencing {#s3c}
----------

The *KRTAP2-3* and *KRTAP2-4* genes were sequenced in the two hemizygous patients. No mutations were identified in *KRTAP2-4*, while the variation c.218G\>A (p.Cys73Tyr), that is reported in dbSNP as rs113397060, was identified. *KRTAP2-3* sequencing was extended to parental samples and the entire patient--control cohorts. One more patient and one control were homozygous (A/A) for this substitution.

Sequencing of the *TSPYL6* gene in the entire patient cohort revealed no mutations.

Discussion {#s4}
==========

Out of a group of 26 patients with POI, we have identified 11 unique novel aberrations in 11 patients, using a customized high-resolution array-CGH platform. Our detection rate is comparable to [@DEU149C22]), and higher than studies using platforms with lower resolution ([@DEU149C1]; [@DEU149C25]; [@DEU149C27]).

One change affects *GDF9* and the other 10 involve new regions. Maternally inherited changes, even though less likely pathogenic if assuming a haploinsufficiency mechanism, have not been excluded by default as autosomal recessive inheritance, and polygenic or environmental factor affecting phenotype penetrance cannot be excluded.

GDF9 on 5q31.1 {#s4a}
--------------

A duplication affecting *GDF9* was detected in Patient 20 with SA at 15 years of age (Fig. [1](#DEU149F1){ref-type="fig"}). This oocyte-secreted factor, expressed from the primary follicle stage, is necessary for normal folliculogenesis and fertility. Mutations affecting the open reading frame of the *GDF9* gene have been associated with POI at a low frequency ([@DEU149C8]; [@DEU149C21]; [@DEU149C46]). No such mutations were identified in our patient cohort.

Within the duplicated region there are three NOBOX-binding elements (NBEs) and an E-box sequence. In mouse NBEs regulate *Gdf9* expression ([@DEU149C5]), and the E-box sequence is a target for transcription factors necessary for the ovarian specific expression of *Gdf9* ([@DEU149C44]). Both the NBEs and the E-box are conserved between mice and humans, as well as several other species. Thus, they are likely important also for the regulation of human *GDF9* expression ([@DEU149C5]; [@DEU149C44]). It is likely that the duplication causes altered GDF9 expression in the developing ovary, leading to POI. This represents the first mutation identified affecting the regulatory region of *GDF9*.

An enrichment of CNVs has been identified in promoter regions, suggesting that promoter sequences can be mildly unstable. This is a suggested evolutionary mechanism for changes in gene regulation ([@DEU149C6]).

Candidate genes {#s4b}
---------------

### *TSPY-Like 6*, *acylphosphatase 2*, *muscle type 1* and *C2ORF73* on *2p16.2* {#s4b1}

The deletion, affecting *TSPY-Like 6* (*TSPYL6*) *and acylphosphatase 2*, *muscle type 1* (*ACYP2*), in Patient 1 was not inherited from the mother. The *TSPYL6* gene function is unknown, but homozygous mutations of *TSPYL1* (*TSPY-Like 1*) have been found to cause dysgenesis of the testis and sudden infant death syndrome (MIM 608800). We considered *TSPYL6* an interesting candidate gene for POI and sequenced the entire patient cohort, but no inactivating mutations were identified.

*ACYP2* encodes a muscle type form of acylphosphatase 2 and we consider it a less likely candidate for POI. The deletion occurs just upstream of *C2ORF73*, an uncharacterized gene expressed in both ovaries and testis. A positional effect of the deletion on this gene expression cannot be excluded as a potential cause of POI.

### Multiple C2 domains, transmembrane 2 on 15q26.2 {#s4b2}

In two unrelated patients with PA (Patients 3 and 5), a 39 kb deletion was detected, removing a large part of intron 1 in one of the several isoforms of the multiple C2 domains, transmembrane 2 (*MCTP2*) gene (ENST00000543482). MCTP2 is a transmembrane protein that binds calcium in the absence of phospholipids. The deletion could affect splicing or regulation or have no effect at all. It is difficult to find an immediate connection between *MCTP2* and POI with the available data.

### SWI/SNF-related matrix-associated, actin-dependent regulator of chromatin subfamily c member 1 and chondroitin sulfate proteoglycan 5 on 3p21.31 {#s4b3}

A 135 kb duplication on chromosome 3p21.31 was found in Patient 4 with PA, spanning the SWI/SNF-related matrix-associated, actin-dependent regulator of chromatin subfamily c member 1 (*SMARCC1*) gene and at least the first two exons of the *CSPG5* gene. SMARCC1 is a member of the SWI/SNF family of proteins that regulate transcription by chromatin remodeling. It is highly expressed in both follicle and ovarian stroma cells. Chondroitin sulfate proteoglycan 5 (CSPG5) is a proteoglycan that may function as a differentiation factor. In mice, there is a sex differential expression profile of *Cspg5* in *Sf1*+ somatic cells in developing gonads at embryonic day 12.5 (E12.5) and E13.5 ([@DEU149C29]) indicating a potential role in gonad differentiation. We consider both *SMARCC1* and *CSPG5* possible candidate genes for POI.

### Calcium channel, voltage-dependent l type alpha 1C subunit on 12p13.33 {#s4b4}

Patient 9, with PA, has a maternally inherited duplication involving the calcium channel, voltage-dependent l type alpha 1C subunit (*CACNA1C*) gene, likely not affecting expression as loss of function mutations causes autosomal dominant cardiac conduction abnormalities (Brugada syndrome, MIM 611875; Timothy syndrome, MIM 601005). We do not consider *CACNA1C* a candidate gene for POI.

### SH3-domain GRB2-like 3 on 15q25.2 {#s4b5}

Patient 12, presenting with PA, carries a maternally inherited duplication of almost the entire sequence of the first intron of the *SH3GL3* gene. SH3-domain GRB2-like 3 (*SH3GL3*) expression is abundant in testis ([@DEU149C35]), where it is believed important for spermatogenesis ([@DEU149C24]). Moderate expression in follicle cells is reported in the Human Protein Atlas. SH3GL3 interacts with the similar protein SH3GL2 (SH3-domain GRB2-like-2) ([@DEU149C13]) that in mice *Sh3Gl2* has a sex differential expression profile at E12.5 and E13.5 ([@DEU149C29]). An association between *SH3GL3* and POI should be further investigated.

### Dynein axonemal heavy chain 6 on 2p11.2 {#s4b6}

In Patient 21 we have identified a 171 kb deletion that removes at least 52 of the 77 exons of the dynein axonemal heavy chain 6 (*DNAH6*) gene encoding a heavy axonemal dynein chain. Dyneins are microtubule-associated motor protein complexes, important for ciliar and flagellar motility. There are heavy, light and intermediate chains. The mouse intermediate chain *Dnaic2* (*dynein*, *axonemal intermediate chain 2*) has been found on the surface of oocytes in secondary and antral stages, but not in primordial or primary follicles suggesting a role for dyneins in ovarian development ([@DEU149C45]).

Interestingly, in a previous array-CGH study a smaller but partially overlapping deletion of *DNAH6* was detected in a patient with secondary amenorrhea (Fig. [2](#DEU149F2){ref-type="fig"}) ([@DEU149C22]) strengthening the possible role for *DNAH6* in POI. Another study has also identified the related *DNAH5* as a candidate gene for POI ([@DEU149C1]). Mutations in *DNAH5* are otherwise known to cause primary ciliary dyskinesia (PCD, MIM244400). We believe that *DNAH6* is a very interesting candidate gene for POI. Figure 2*DNAH6* deletion. (**A**) Representation of an array-CGH result from the Cytosure software. The duplicated segment is indicated by blue background with a negative baseline offset. Blue dispersed dots represent oligomarkers. Blue arrows on bottom indicate gene location and purple vertical lines represent exons. The *DNAH6* gene is shown with previous name *DNHL1*. The black horizontal line on bottom represents the location of deletion. Chromosome ideogram shown on top with the current segment magnification indicated by blue background color. (**B**) Representation from the UCSC genome browser, GRCh37/hg19 assembly. The green line represents the deletion detected in Patient 21. The orange line shows the deletion reported by Ledig *et al.* Vertical black lines represent MLPA probes.

### KRTAP2-3 and KRTAP2-4 on 17q21.2 {#s4b7}

A 9 kb deletion encompassing the *KRTAP2-3* and *KRTAP2-4* genes was identified in two unrelated patients with SA and by MLPA screening one additional hemizygous patient was found.

We hypothesized an autosomal recessive causative mechanism, and by sequencing identified a potentially damaging amino acid substitution in the *KRTAP2-3* gene in the hemizygous patients and in homozygous form in one more patient with POI. However, also one control was found to be homozygous for the substitution, contradicting *KRTAP2-3* mutations as causative for POI. It is possible that the identified *KRTAP2-3* and *KRTAP2-4* deletion is a normal variant in the Swedish population as also two controls are hemizygous.

### Purinergic receptor P2Y G-protein coupled 8 and acetylserotonin *O*-methyltransferase-like on Xp22.33 {#s4b8}

In addition to a deletion of *KRTAP2-3* and *KRTAP2-4*, Patient 22 also carries a duplication in the pseudoautosomal region 1 on the X chromosome. The duplication includes the last exon of purinergic receptor P2Y G-protein coupled 8 (*P2RY8*) and the first exon of the *ASMTL* gene. P2RY8 is a G-protein coupled receptor expressed in lymphocytes. Acetylserotonin *O*-methyltransferase-like (ASMTL) is a generally expressed enzyme, with high levels in ovarian follicle cells. We consider both *P2RY8* and *ASTML* less likely candidate genes for POI.

### Del 19p13.3 {#s4b9}

A 128 kb deletion on chromosome 19 was also identified in Patient 22 affecting six genes: *TJP3*, *APBA3*, *MRPL54*, *RAX2*, *MATK* and *zinc finger RNA-binding protein 2* (*ZFR2*).

Knock-out mouse models for *TJP3* ([@DEU149C43]), *APBA3* ([@DEU149C14]) and *MATK* ([@DEU149C23]) have been described without particular phenotypes and with normal fertility excluding these genes as candidates for POI.

*MRPL54* encodes for a mitochondrial ribosome subunit necessary for the synthesis of mitochondrial proteins ([@DEU149C18]). Defects of mitochondrial protein synthesis lead to a more wide and severe phenotype than isolated POI. *RAX2* heterozygous missense mutations cause age-related macular degeneration (MIM 610362) and cone-rod dystrophy type 11 (MIM 610381). We exclude *MRPL54* and *RAX2* as candidate genes for POI.

*ZFR2* has no known function, but is expressed in many adult cell types, including ovarian follicle and stroma cells, as well as in female gametocytes and germ cells ([@DEU149C12]). Ovarian biopsies from the patient show bilateral complete lack of oocytes and follicles and we consider *ZFR2* an interesting candidate gene for POI.

### KAT8 regulatory NSL complex subunit 1-like on 2q34 {#s4b10}

In Patient 23, with SA at 17, we detected a 36 kb deletion removing the first coding exon of the KAT8 regulatory NSL complex subunit 1-like (*KANSL1L*) gene on chromosome 2q34. *KANSL1L*, together with *KANSL1* on chromosome 17, are the human homologs of the *Drosophila Waharan* gene ([@DEU149C26]). KANSL1 is a regulator of KAT8 influencing gene expression through histone H4 lysine 16 acetylation ([@DEU149C28]). Mutations in this gene cause 17q21.31 microdeletion syndrome (MIM 612452). No specific information on KANSL1L function is reported, but as an altered chromatin acetylation could possibly affect developing germ cells and follicle formation, we consider *KANSL1L* a potential candidate gene for POI.

Conclusion {#s5}
==========

Using array-CGH, we have identified the first mutation affecting the regulatory region of *GDF9* in a patient with SA, most likely pathogenic. Importantly, the small, 475 bp duplication would not have been detected without the customized probe enrichment, making clear that platform resolution and probe targeting are crucial. We have also identified a second *DNAH6* deletion in a patient with SA, corroborating *DNAH6* as a candidate gene for POI. In addition, we describe several novel candidate genes such as *TSPYL6*, *SMARCC1*, *CSPG5* and *ZFR2*.

We consider array-CGH a powerful tool to identify candidate genes for POI and we recommend that patients without a molecular diagnosis should undergo analysis for copy number alterations. Soon next generation sequencing will be available and able to provide reliable data on copy numbers, once this occurs whole genome sequencing should be considered for diagnostics of POI patients, as most known causative genes can either harbor small pathogenic sequence changes or be present in abnormal copy numbers.
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[^1]: PA, primary amenorrhea; SA, secondary amenorrhea. ^a^Reference value: \<30 IU/l.

[^2]: All coordinates are given using the NCBI36/hg18 build. Pat no., patient number; Age at amen., Age at amenorrhea; Chr. Band., chromosomal band; Del., deletion; Dup., duplication; PA, primary amenorrhea; NA, no available sample.

[^3]: ^a^Homozygous deletion.
